INmune Bio adds two executives to its board of directors

INmune Bio Inc. (NASDAQ: INMB) announced the appointments of R. Duane Clark II and James Sapirstein to its board of directors, according to a company press release dated Sept. 14, 2026.

Clark currently serves as General Manager of U.S. Rare Diseases at Sanofi, where he oversees a business spanning seven rare-disease brands with full profit-and-loss responsibility. He has more than 40 years of experience in pharmaceutical and biotechnology, including roles at Astellas Pharma, Ortho Biotech, and Encysive Pharmaceuticals.

Sapirstein brings more than 40 years of biopharmaceutical experience, including senior positions at Gilead Sciences, Bristol Myers Squibb, Hoffmann-La Roche, Eli Lilly, and Serono Laboratories. He founded Tobira Therapeutics, which was later acquired by Allergan in a transaction with total potential consideration of up to approximately $1.7 billion, including contingent milestone payments.

The appointments come as INmune Bio advances Ebstrocel, its cell therapy candidate targeting recessive dystrophic epidermolysis bullosa (RDEB), toward potential commercialization. The company has stated plans to file a Marketing Authorization Application with the UK Medicines and Healthcare products Regulatory Agency in 2026 and with the European Medicines Agency in 2027, alongside a planned U.S. Biologics License Application submission.

"Duane's rare-disease leadership leading a major rare-disease business will strengthen our planning for market access and potential commercialization of Ebstrocel," said David Moss, Chief Executive Officer of INmune Bio. "James's business development, licensing, and financing experience will support our evaluation of strategic opportunities for our broader pipeline."

INmune Bio also has a second late-stage platform, XPro1595, a selective TNF inhibitor targeting neuroinflammation in early Alzheimer's disease, which has received FDA Fast Track designation and completed an End-of-Phase 2 meeting.

You May Also Be Interested In

• BioMarin adds Bristol Myers Squibb research chief to its board
• FDA approves Biofrontera's Ameluz for superficial basal cell carcinoma
• FDA grants Armata Pharmaceuticals breakthrough therapy status for AP-SA02